Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:2298-2306
Published online before print October 29, 2007, doi: 10.1161/CIRCULATIONAHA.107.692764
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
116/20/2298    most recent
CIRCULATIONAHA.107.692764v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pawlinski, R.
Right arrow Articles by Mackman, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pawlinski, R.
Right arrow Articles by Mackman, N.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Nucleotide
*Protein*UniGene
*Substance via MeSH
Medline Plus Health Information
*Heart Attack
Related Collections
Right arrow Other myocardial biology
Right arrow Thrombin
Right arrow Other Vascular biology
Right arrow Animal models of human disease

(Circulation. 2007;116:2298-2306.)
© 2007 American Heart Association, Inc.


Molecular Cardiology

Protease-Activated Receptor-1 Contributes to Cardiac Remodeling and Hypertrophy

Rafal Pawlinski, PhD; Michael Tencati, BS; Craig R. Hampton, MD; Tetsuro Shishido, MD, PhD; Tara A. Bullard, PhD; Liam M. Casey, MD; Patricia Andrade-Gordon, PhD; Matthias Kotzsch, MD; Denise Spring, PhD; Thomas Luther, MD; Jun-ichi Abe, MD, PhD; Timothy H. Pohlman, MD; Edward D. Verrier, MD; Burns C. Blaxall, PhD; Nigel Mackman, PhD

From The Scripps Research Institute (R.P., M.T., N.M.), Department of Immunology, La Jolla, Calif; University of Washington (C.R.H., D.S., T.H.P., E.D.V.), Division of Cardiothoracic Surgery, Seattle, Wash; University of Rochester Medical Center (T.S., T.A.B., L.M.C., J.A., B.C.B.), Cardiovascular Research Institute, Rochester, New York; Johnson & Johnson Pharmaceutical Research and Development, LLC (P.A.-G.), Spring House, Pa; and Institute of Pathology (M.K., T.L.), Technical University of Dresden, Dresden, Germany.

Correspondence to Nigel Mackman, PhD, The Scripps Research Institute, Department of Immunology, SP30-3040, 10550 N Torrey Pines Rd, La Jolla, CA 92037. E-mail nmackman{at}scripps.edu

Received January 25, 2007; accepted September 14, 2007.

Background— Protease-activated receptor-1 (PAR-1) is the high-affinity receptor for the coagulation protease thrombin. It is expressed by a variety of cell types in the heart, including cardiomyocytes and cardiac fibroblasts. We have shown that tissue factor (TF) and thrombin contribute to infarct size after cardiac ischemia-reperfusion (I/R) injury. Moreover, in vitro studies have shown that PAR-1 signaling induces hypertrophy of cardiomyocytes and proliferation of cardiac fibroblasts. The purpose of the present study was to investigate the role of PAR-1 in infarction, cardiac remodeling, and hypertrophy after I/R injury. In addition, we analyzed the effect of overexpression of PAR-1 on cardiomyocytes.

Methods and Results— We found that PAR-1 deficiency reduced dilation of the left ventricle and reduced impairment of left ventricular function 2 weeks after I/R injury. Activation of ERK1/2 was increased in injured PAR-1–/– mice compared with wild-type mice; however, PAR-1 deficiency did not affect infarct size. Cardiomyocyte-specific overexpression of PAR-1 in mice induced eccentric hypertrophy (increased left ventricular dimension and normal left ventricular wall thickness) and dilated cardiomyopathy. Deletion of the TF gene in cardiomyocytes reduced the eccentric hypertrophy in mice overexpressing PAR-1.

Conclusions— Our results demonstrate that PAR-1 contributes to cardiac remodeling and hypertrophy. Moreover, overexpression of PAR-1 on cardiomyocytes induced eccentric hypertrophy. Inhibition of PAR-1 after myocardial infarction may represent a novel therapy to reduce hypertrophy and heart failure in humans.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
CirculationHome page
J. L. Strande
Letter by Strande Regarding Article "Protease-Activated Receptor-1 Contributes to Cardiac Remodeling and Hypertrophy"
Circulation, June 17, 2008; 117(24): e495 - e495.
[Full Text] [PDF]


Home page
CirculationHome page
R. Pawlinski, M. Tencati, C. R. Hampton, D. Spring, T. H. Pohlman, E. D. Verrier, T. Shishido, T. A. Bullard, L. M. Casey, J.-i. Abe, et al.
Response to Letter Regarding Article, "Protease-Activated Receptor-1 Contributes to Cardiac Remodeling and Hypertrophy"
Circulation, June 17, 2008; 117(24): e496 - e496.
[Full Text] [PDF]